CONFERENCE PROGRAM

Monday, April 29

7:00 a.m.-8:00 a.m. CONTINENTAL BREAKFAST

8:00 a.m.-9:30 a.m. OPENING SESSION AND KEYNOTE LECTURE 1
8:00 a.m.-8:15 a.m. Welcome remarks/Introduction
James W. Rocco, The Ohio State University Wexner Medical Center, Columbus, OH
8:15 a.m.-8:30 a.m. In memoriam: Drs. Waun-Ki Hong and John Mendelsohn
Christine H. Chung, Moffitt Cancer Center, Tampa, FL
8:30 a.m.-9:30 a.m. Cancer evolution through the lens of single-cell genomics
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, TX

9:30 a.m.-9:55 a.m. COFFEE BREAK

9:55 a.m.-12:00 p.m. PLENARY SESSION 1: NOVEL TARGETS AND BIOMARKERS IN HEAD AND NECK CANCER
Session Chair: Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, TX
9:55 a.m.-10:20 a.m. Utilizing patient-derived xenografts for prognostication and biomarker discovery
Laurie E. Ailles, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
10:20 a.m.-10:45 a.m. Genetic and immunogenomic biomarkers in advanced head and neck cancer
Luc G.T. Morris, Memorial Sloan Kettering Cancer Center, New York, NY
10:45 a.m.-11:10 a.m. Novel approaches to study the tumor-stroma interaction and translate immuno-directed therapies
Antonio Jimeno, University of Colorado Cancer Center, Aurora, CO
11:10 a.m.-11:35 a.m. Intratumor genetic heterogeneity as a predictive biomarker in head and neck squamous cell carcinoma
James W. Rocco, The Ohio State University Wexner Medical Center, Columbus, OH
11:35 a.m.-11:47 a.m. HPV structure and functional alterations impact prognosis in HPV (+) oropharyngeal squamous cell carcinoma*
Jose P. Zevallos, Washington University School of Medicine in St. Louis, St. Louis, MO
11:47 a.m-11:59 p.m. Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status*
Anthony Nichols, Western University, London, ON, Canada

*Short talk from proffered abstract

AACR-AHNS HEAD AND NECK CANCER CONFERENCE
12:00 p.m.-1:45 p.m.  FREE TIME / LUNCH ON OWN

12:30 p.m.-1:30 p.m.  GRANT EDUCATION SESSION (OPTIONAL)
12:30 p.m.-1:00 p.m.  Head and neck cancer research investment at NIDCR
Chiayeng Wang, National Institute of Dental and Craniofacial Research, Bethesda, MD

1:00 p.m.-1:30 p.m.  Panel discussion on grant writing
Patrick K. Ha, University of California San Francisco, San Francisco, CA
Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, TX
Richard J. Wong, Memorial Sloan Kettering Cancer Center, New York, NY
Jose P. Zevallos, Washington University School of Medicine in St. Louis, St. Louis, MO

1:45 p.m.-2:30 p.m.  KEYNOTE LECTURE 2
Understanding tumor dynamics and heterogeneity
Gad Getz, Broad Institute, Cambridge, MA

2:30 p.m.-4:10 p.m.  PLENARY SESSION 2: SINGLE-CELL ANALYSIS
Session Chair: Wendell G. Yarbrough, University of North Carolina School of Medicine, Chapel Hill, NC

2:30 p.m.-2:55 p.m.  Solving biomedical challenges through single-cell genomics approach
Alexandra Chloe Villani, Broad Institute of MIT and Harvard, Cambridge, MA

2:55 p.m.-3:20 p.m.  Understanding programs of invasion and metastasis in head and neck cancer
Sidharth V. Puram, Washington University in St. Louis, St. Louis, MO

3:20 p.m.-3:45 p.m.  Beyond counting: Imaging flow cytometry-based detection of therapeutic molecular targets in circulating tumor cells
Ingeborg Tinhofer, Charité – Universitätsmedizin Berlin, Berlin, Germany

3:45 p.m.-3:57 p.m.  The tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC): Investigating new aspects of known cell types using single-cell RNA sequencing*
Aditi Kulkarni, University of Pittsburgh, Pittsburgh, PA

3:57 p.m.-4:09 p.m.  RNA sequencing of salivary mucoepidermoid carcinoma reveals distinct molecular profiles based on histologic grade*
Siddharth Sheth, University of North Carolina at Chapel Hill, Chapel Hill, NC

4:10 p.m.-4:40 p.m.  AFTERNOON BREAK

*Short talk from proffered abstract
CONFERENCE PROGRAM

4:40 p.m.-6:20 p.m.  PLENARY SESSION 3: TME, METABOLICOSMS, HYPOXIA
   Session Chair: Jose P. Zevallos, Washington University School of Medicine in St. Louis, St. Louis, MO
   4:40 p.m.-5:05 p.m.  Targeting glutamine metabolism as a means of enhancing immunotherapy for cancer
                      Jonathan D. Powell, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
   5:05 p.m.-5:30 p.m.  Reversal of immunotherapy resistance through hypoxia reduction
                      Michael A. Curran, The University of Texas MD Anderson Cancer Center, Houston, TX
   5:30 p.m.-5:55 p.m.  Metabolic barriers to effective immunotherapy of cancer
                      Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, PA
   5:55 p.m.-6:20 p.m.  Effects of tobacco smoking on the tumor microenvironment in head and neck squamous cell carcinoma
                      Christine H. Chung, Moffitt Cancer Center, Tampa, FL

6:25 p.m.–8:00 p.m.  POSTER SESSION A / RECEPTION

Tuesday, April 30

7:00 a.m.-8:00 a.m.  CONTINENTAL BREAKFAST

8:00 a.m.-8:45 a.m.  KEYNOTE LECTURE 3
   Targeting the DNA damage response in head and neck cancers
   Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, TX

8:45 a.m.-10:50 a.m.  PLENARY SESSION 4: IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPIES, IMMUNOBIOLGY, TARGETING THE IMMUNE SYSTEM
   Session Chair: Robert L. Ferris, University of Pittsburgh Cancer Institute, Pittsburgh, PA
   8:45 a.m.-9:10 a.m.  Suppression of intratumoral regulatory T cells restores radiosensitivity in head and neck cancer: Role for Stat3 inhibition
                      Sana D. Karam, University of Colorado Denver, Aurora, CO
   9:10 a.m.-9:35 a.m.  Augmenting anti-PD1 activity via an HLA-agnostic, mutation burden-independent, personalized neoantigen vaccine strategy
                      Ezra E.W. Cohen, UCSD Moores Cancer Center, San Diego, CA
9:35 a.m.-10:00 a.m. Cellular interactions and regulatory mechanisms in head and neck cancer
Dario A. Vignali, University of Pittsburgh School of Medicine, Pittsburgh, PA

10:00 a.m.-10:25 a.m. Interrogating anti-PD1 immunotherapy resistance mechanisms
Ravindra Uppaluri, Dana-Farber Cancer Center, Boston, MA

10:25 a.m.-10:37 a.m. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma*
Daniel Faden, Massachusetts Eye and Ear Institute, Boston, MA

10:37 a.m.-10:49 a.m. Tumor-infiltrating B cells colocalize with CD4 T effector cells within tertiary lymphoid structures to present antigen and educate the antitumor immune response in human primary tumors*
Tulia Bruno, University of Pittsburgh, Pittsburgh, PA

10:50 a.m.-11:05 a.m. COFFEE BREAK

11:05 a.m.-12:25 p.m. PLENARY SESSION 5: UPDATES ON CLINICAL TRIALS
Session Chair: Cherie-Ann O. Nathan, Louisiana State University Health Sciences Center, Shreveport, LA

11:05 a.m.-11:20 a.m. Immune checkpoint inhibition in metastatic/recurrent head and neck cancer
Barbara A. Burtness, Yale Cancer Center, New Haven, CT

11:20 a.m.-11:35 a.m. Radiotherapy plus cetuximab or cisplatin in human papilloma virus-positive oropharyngeal cancer (NRG 1016): A randomized multicenter noninferiority trial
Andy M. Trotti, Moffitt Cancer Center, Tampa, FL

11:35 a.m.-11:50 a.m. Integrating head and neck cancer immunotherapy into locally advanced treatment
Robert L. Ferris, University of Pittsburgh Cancer Institute, Pittsburgh, PA

11:50 a.m.-12:25 p.m. Panel discussion

12:25 p.m.-1:55 p.m. POSTER SESSION B / LUNCH

1:55 p.m.-4:00 p.m. PLENARY SESSION 6: MECHANISMS OF THERAPY RESPONSE AND RESISTANCE
Session Chair: Joseph A. Califano, University of California, San Diego, San Diego, CA

1:55 p.m.-2:20 p.m. Understanding genetic mediators of response and resistance to immune checkpoint blockade therapy
Nadeem Riaz, Memorial Sloan Kettering Cancer Center, New York, NY

2:20 p.m.-2:45 p.m. Intrinsic tumor genomic and metabolic factors leading to immunoresistance
Patrick Hwu, The University of Texas MD Anderson Cancer Center, Houston, TX

*Short talk from proffered abstract
CONFERENCE PROGRAM

2:45 p.m.-3:10 p.m.  Molecular correlates of T cell-inflamed and non-T cell-inflamed tumors
Jason J. Luke, University of Chicago, Chicago, IL

3:10 p.m.-3:35 p.m.  Radiation as a way to flip the switch: Resistance to responder in HNSCC
David Raben, University of Colorado Cancer Center, Aurora, CO

3:35 p.m.-3:47 p.m.  WEE1 inhibition triggers premature mitotic entry in HPV16-E6 expressing cells independent of p53*
Ahmed Diab, Fred Hutchinson Cancer Research Center, Seattle, WA

3:47 p.m.-3:59 p.m.  Inhibition of ATR as a therapeutic strategy to overcome cisplatin resistance in HNSCC*
Antje Lindemann, The University of Texas MD Anderson Cancer Center, Houston, TX

4:00 p.m.  CLOSING REMARKS
Neil D. Gross, The University of Texas MD Anderson Cancer Center, Houston, TX

4:10 p.m.  DEPARTURE

*Short talk from proffered abstract